Pharma Market Access Insights - from Petauri Evidence
Petauri Evidence
71 episodes
4 days ago
Send us a text What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acces...
All content for Pharma Market Access Insights - from Petauri Evidence is the property of Petauri Evidence and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acces...
Pharma Market Access Insights - from Petauri Evidence
20 minutes
1 year ago
Engage NHS healthcare decision-makers with RWD
Discover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted partner. Watch this 20-minute discussion between Iain Shield (Associate Director – Market Access) and Ben Spurr (Head of Partnerships) to discover how...
Pharma Market Access Insights - from Petauri Evidence
Send us a text What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acces...
